We postulated the higher sensitivity and specificity of Duplex Sequencing would more accurately detect and quantify low-level, pretreatment ABL1 mutations compared to conventional techniques and could resolve historical uncertainties around the clinical importance of such mutations, thus providing important insights into optimal frontline TKI selection for patients with Ph + ALL. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.